{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(11)"],"submitter":["Everitt ML"],"pubmed_abstract":["To combat pandemics, there is a need for rapid point-of-care diagnostics to identify infected patients and to track the spread of the disease. While recent progress has been made in response to COVID-19, there continues to be a need for point-of-care diagnostics capable of detecting biomarkers-such as antibodies-in whole blood. We have recently reported the development of thermally responsive alkane partitions (TRAPs) for the automation of point-of-care immuno-magnetic assays. Here, we demonstrate the use of TRAPs to enable sample-to-answer detection of antibodies against the SARS-CoV-2 virus in whole blood samples. We report a limit of detection of 84 pg/mL, well below the clinically relevant threshold. We anticipate that the TRAP-enabled sample-to-answer immunoassay can be used to track "],"journal":["Biosensors"],"pagination":["1030"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9688217"],"repository":["biostudies-literature"],"pubmed_title":["Sample-to-Answer Immuno-Magnetic Assay Using Thermally Responsive Alkane Partitions."],"pmcid":["PMC9688217"],"pubmed_authors":["Boegner DJ","White IM","Everitt ML"],"additional_accession":[]},"is_claimable":false,"name":"Sample-to-Answer Immuno-Magnetic Assay Using Thermally Responsive Alkane Partitions.","description":"To combat pandemics, there is a need for rapid point-of-care diagnostics to identify infected patients and to track the spread of the disease. While recent progress has been made in response to COVID-19, there continues to be a need for point-of-care diagnostics capable of detecting biomarkers-such as antibodies-in whole blood. We have recently reported the development of thermally responsive alkane partitions (TRAPs) for the automation of point-of-care immuno-magnetic assays. Here, we demonstrate the use of TRAPs to enable sample-to-answer detection of antibodies against the SARS-CoV-2 virus in whole blood samples. We report a limit of detection of 84 pg/mL, well below the clinically relevant threshold. We anticipate that the TRAP-enabled sample-to-answer immunoassay can be used to track ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T16:11:53.445Z","creation":"2025-04-19T16:11:53.445Z"},"accession":"S-EPMC9688217","cross_references":{"pubmed":["36421148"],"doi":["10.3390/bios12111030"]}}